Bioxytran Secures $1.6M Investment from TRITON FUNDS to Drive Clinical Trials

• Bioxytran enters a $1.6M stock purchase agreement with TRITON FUNDS to fund clinical trials and working capital.

• Proceeds will pay off $805,000 in existing debt, with the balance supporting drug development and operational needs.

Bioxytran, Inc., a clinical-stage biotechnology company focusing on therapies for viral diseases and fibrotic conditions, has announced a $1.6 million common stock purchase agreement with TRITON FUNDS LP. The funds will be used to pay down existing debt, advance pre-clinical and clinical trials, and support working capital requirements.

As part of the agreement, $805,000 will go toward settling an existing noteholder’s debt, while the remaining funds will enable Bioxytran to progress regulatory trials for its drugs targeting pandemics and other diseases. This marks the second and larger investment from TRITON FUNDS in the company, reinforcing their confidence in Bioxytran’s potential.

Commenting on the partnership, Axel Olson, Equity Analyst and Entrepreneur in Residence at TRITON FUNDS, stated, “We view this investment as a stepping stone for follow-on investment of a more substantial nature. From our point of view, Bioxytran is a highly undervalued asset with exceptionally strong clinical trial data.”

Additionally, Bioxytran’s management has forfeited over $460,000 in accrued salaries and expenses, showcasing their commitment to the company’s long-term success.

Dr. David Platt, CEO of Bioxytran, added, “This investment showcases TRITON FUNDS’ commitment to our success. It provides momentum to advance our regulatory pathway and FDA trial of PLM, while also addressing pandemic viruses with our broad-spectrum antiviral capabilities.”